Evidence map›Paper›PMID 41176574›Full record

Trial reportBritish journal of cancer2026

Compound staphylococcal lysostaphin for oral mucositis prophylaxis in hematopoietic stem cell transplantation recipients: a non-inferiority randomized trial.

Xiaoyu Zhou, Zhengwen Pan, Weiwei Zhou, Jianli Zhang, Liwei Xu, Shuyi Ding, Liying Zeng, Yini Huang, Zhenzhen Fang, Weilin Pang

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06791746 (Compound Staphylococcal Lysostaphin Versus Chlorhexidine Mouthrinse for the Prophylaxis of Oral Mucositis in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06791746 phase3completednot on this map

Compound Staphylococcal Lysostaphin Versus Chlorhexidine Mouthrinse for the Prophylaxis of Oral Mucositis in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: a Randomized, Controlled, Non-inferiority Clinical Tria

TypeinterventionalSponsorZhejiang UniversityRan2020 to 2022Enrolled388ConditionsStem Cell Transplant Complications, Oral MucositisArmscompound Staphylococcal lysostaphin mouthrinse, chlorhexidine mouthrinse
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaoyu ZhouNursing Department, the First Affiliated Hospital of Medical College, Zhejiang University, Hangzhou, China. 19840719@zju.edu.cn.ORCID http://orcid.org/0000-0003-4788-6139
Zhengwen PanNursing Department, the First Affiliated Hospital of Medical College, Zhejiang University, Hangzhou, China.
Weiwei ZhouNursing Department, the First Affiliated Hospital of Medical College, Zhejiang University, Hangzhou, China.
Jianli ZhangNursing Department, the First Affiliated Hospital of Medical College, Zhejiang University, Hangzhou, China.
Liwei XuNursing Department, the First Affiliated Hospital of Medical College, Zhejiang University, Hangzhou, China.
Shuyi DingNursing Department, the First Affiliated Hospital of Medical College, Zhejiang University, Hangzhou, China.
Liying ZengNursing Department, the First Affiliated Hospital of Medical College, Zhejiang University, Hangzhou, China.
Yini HuangNursing Department, the First Affiliated Hospital of Medical College, Zhejiang University, Hangzhou, China.
Zhenzhen FangNursing Department, the First Affiliated Hospital of Medical College, Zhejiang University, Hangzhou, China.
Weilin PangNursing Department, the First Affiliated Hospital of Medical College, Zhejiang University, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChlorhexidine mouthrinse offers a cost-effective approach to preventing oral mucositis (OM) in anti-tumour treatment, yet it might cause tooth discoloration, unpleasant taste, and pain. To compare compound Staphylococcal lysostaphin (CSL) mouthrinse to chlorhexidine mouthrinse in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients.

methodsThis randomised, controlled, non-inferiority clinical trial (NCT06791746) randomised adult patients who were scheduled for myeloablative conditioning and allo-HSCT to receive OM prophylaxis using CSL mouthrinse or chlorhexidine mouthrinse. The primary endpoint was the cumulative incidence of oral mucositis, with a non-inferiority margin of 15%.

resultsAmong 196 participants in the CSL mouthrinse group and 197 in the chlorhexidine mouthrinse group, ninety-four (48.0%) and 105 (53.3%) developed OM, respectively. The absolute risk difference was -5.3% (95% CI: -15.6, 4.7), with a upper limit of 95% CI did not exceed the non-inferiority margin. The average pain score was significantly lower with CSL mouthrinse (0.45 ± 1.06 vs. 0.85 ± 1.39, P = 0.002), supported by the analysis of distribution of pain score (P < 0.001). The time to OM onset and cumulative days with OM were comparable between the two groups (both P > 0.05).

conclusionsCSL mouthrinse had non-inferior prophylactic efficacy in reducing OM occurrence in patients undergoing myeloablative conditioning allo-HSCT compared to chlorhexidine mouthrinse, with less pain intensity.

Indexed as

Hematopoietic Stem Cell TransplantationMouthwashesStomatitisAdultAgedChlorhexidineFemaleHumansMaleMiddle AgedTransplantation ConditioningChlorhexidineMouthwashes

Identifiers

PMID41176574
PMCPMC12820162

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.